Actively Recruiting

Phase 1
Age: 18Years - 60Years
All Genders
Healthy Volunteers
NCT06105151

Study of the Safety, Tolerability, Pharmacokinetics and Food Effects of VV119 Capsules in Chinese Healthy Volunteers

Led by Vigonvita Life Sciences · Updated on 2025-06-11

82

Participants Needed

1

Research Sites

109 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study will consist of 2 parts: Part Ⅰ - Single Ascending Dose (SAD) study, Part Ⅱ - Food Effect (FE) study

CONDITIONS

Official Title

Study of the Safety, Tolerability, Pharmacokinetics and Food Effects of VV119 Capsules in Chinese Healthy Volunteers

Who Can Participate

Age: 18Years - 60Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Male participants aged 18 to 45 years with body weight no less than 50.0 kg
  • Female participants aged 18 to 60 years with body weight no less than 45.0 kg and BMI between 19.0 to 26.0 kg/m2
  • Medically healthy with normal or clinically insignificant physical exam, vital sign, lab, and ECG results
  • Male subjects willing to use effective contraception during the study and for 3 months after
  • Females not of child-bearing potential
  • Able to understand and follow study instructions and provide informed consent
Not Eligible

You will not qualify if you...

  • History or current diseases affecting major systems such as CNS, cardiovascular, respiratory, digestive, urinary, endocrine, blood, or eye diseases
  • History of malignant tumors or other unsuitable diseases
  • Mental disorders, brain dysfunction, suicide risk, or history of self-mutilation
  • Surgical conditions affecting drug absorption or posing risk, including gastrointestinal surgery or urinary obstruction
  • Known allergy to study drug or similar drugs
  • Positive for hepatitis B surface antigen, syphilis antibody, hepatitis C antibody, or HIV antigen/antibody
  • Recent surgery within 3 months, incomplete recovery, or planned surgery during trial
  • Recent blood donation or loss exceeding specified amounts
  • Use of prescription, OTC drugs, vitamins, or herbal products within 2 weeks before screening
  • Use of drugs affecting CYP3A4, CYP3A5, CYP2D6 enzymes within 4 weeks before screening
  • Participation in other clinical trials or use of trial drugs within 3 months
  • Smoking more than 5 cigarettes per day or heavy caffeine intake, or unable to stop during study
  • Alcohol abuse within 1 year or positive alcohol breath test
  • Drug abuse history within 1 year or positive drug screen
  • Family history of sudden cardiac death before age 40
  • Abnormal vital signs or clinically significant ECG abnormalities
  • Abnormal liver, kidney, or prolactin lab values
  • Special dietary needs or dysphagia
  • Refusal to avoid smoking, alcohol, caffeine, or strenuous exercise during trial
  • Directly related to this clinical trial or deemed unsuitable by investigator for other reasons

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Beijing Anding Hospital of Capital Medical University

Beijing, Beijing Municipality, China, 100088

Actively Recruiting

Loading map...

Research Team

H

Huaqing Duan

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here